SSY Group (02005.HK): Nemonoxacin Malate Has Been Approved by the National Medical Products Administration for Registration as an API Used in Marketed Formulations

Zhitong Finance APP news, SSY Group (02005.HK) announced that the group's nemonoxacin malate has been approved by China's National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed formulations.